Wyeth predicts quick response to Tygacil "approvable" letter
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Wyeth anticipates submitting a complete response to FDA's "approvable" letter for a new community-acquired pneumonia indication for its I.V. antibiotic Tygacil (tigecycline) by June 27, the company says after announcing receipt of the letter on May 29. On that timetable, the sNDA would have a user fee goal of Dec. 22. FDA requested additional analyses of the antibiotic "in patients with CAP with illness severe enough to require hospitalization, including those who are at higher risk of mortality," Wyeth says. FDA also asked for benefit/risk information on the potential for liver toxicity; Wyeth maintains that such information was presented to FDA during the review period, noting that "the agency acknowledged in its letter that it had not yet reviewed that information.
You may also be interested in...
Turkish Medtechs Face The Constant Challenge Of Sailing In Stormy Seas
The pandemic has exacerbated the problems of the Turkish medical device industry, which was already struggling for survival and growth in a hostile policy environment. Local blood bag manufacturer Kansuk Laboratory talked to Medtech Insight about the difficulties it faces.
Pipeline Watch: Phase III Readouts For COVID-19, Dry Eye Disease, Uveal Melanoma
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Ireland’s Supply Chain Suffers Due To Brexit And Covid
Medicines for Ireland has released a report focusing on the direct impact of Brexit and COVID-19 on the medicines supply chain. The association has called for long-term plans and solutions instead of temporary fixes for issues related to delays in the import and export of medicines.